Go Pro

Baxter International (BAX) Competitors

Baxter International logo
$22.79 -0.23 (-0.98%)
Closing price 09/18/2026 03:59 PM Eastern
Extended Trading
$22.82 +0.03 (+0.11%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BAX vs. AMN, DVA, BDX, EW, and IDXX

Should you buy Baxter International stock or one of its competitors? Baxter International's main competitors and comparable companies include AMN Healthcare Services (AMN), DaVita (DVA), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), and IDEXX Laboratories (IDXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Baxter International compare to AMN Healthcare Services?

Baxter International (NYSE:BAX) and AMN Healthcare Services (NYSE:AMN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

AMN Healthcare Services has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than AMN Healthcare Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baxter International$11.24B1.05-$957M-$2.07N/A
AMN Healthcare Services$2.73B0.48-$95.70M$2.6812.73

Baxter International currently has a consensus target price of $22.45, suggesting a potential downside of 1.49%. AMN Healthcare Services has a consensus target price of $36.00, suggesting a potential upside of 5.53%. Given AMN Healthcare Services' stronger consensus rating and higher probable upside, analysts clearly believe AMN Healthcare Services is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
AMN Healthcare Services
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

AMN Healthcare Services has a net margin of 3.06% compared to Baxter International's net margin of -9.27%. AMN Healthcare Services' return on equity of 19.92% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
Baxter International-9.27% 16.57% 5.24%
AMN Healthcare Services 3.06%19.92%5.93%

In the previous week, AMN Healthcare Services had 7 more articles in the media than Baxter International. MarketBeat recorded 9 mentions for AMN Healthcare Services and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.92 beat AMN Healthcare Services' score of 0.55 indicating that Baxter International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Baxter International
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
AMN Healthcare Services
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

90.2% of Baxter International shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

AMN Healthcare Services beats Baxter International on 12 of the 16 factors compared between the two stocks.

How does Baxter International compare to DaVita?

Baxter International (NYSE:BAX) and DaVita (NYSE:DVA) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

DaVita has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than DaVita, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Baxter International$11.24B1.05-$957M-$2.07N/A
DaVita$13.64B0.86$746.80M$12.2215.02

90.2% of Baxter International shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 1.9% of DaVita shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DaVita has a net margin of 6.05% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat DaVita's return on equity.

Company Net Margins Return on Equity Return on Assets
Baxter International-9.27% 16.57% 5.24%
DaVita 6.05%-217.63%5.07%

Baxter International has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, DaVita has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, DaVita had 12 more articles in the media than Baxter International. MarketBeat recorded 14 mentions for DaVita and 2 mentions for Baxter International. DaVita's average media sentiment score of 1.01 beat Baxter International's score of 0.92 indicating that DaVita is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Baxter International
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DaVita
8 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Baxter International currently has a consensus target price of $22.45, suggesting a potential downside of 1.49%. DaVita has a consensus target price of $233.43, suggesting a potential upside of 27.14%. Given DaVita's stronger consensus rating and higher possible upside, analysts plainly believe DaVita is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxter International
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
DaVita
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57

Summary

DaVita beats Baxter International on 12 of the 16 factors compared between the two stocks.

How does Baxter International compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

In the previous week, Becton, Dickinson and Company had 6 more articles in the media than Baxter International. MarketBeat recorded 8 mentions for Becton, Dickinson and Company and 2 mentions for Baxter International. Becton, Dickinson and Company's average media sentiment score of 1.05 beat Baxter International's score of 0.92 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Becton, Dickinson and Company has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Becton, Dickinson and Company has a net margin of 4.52% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company4.52% 14.79% 6.93%
Baxter International -9.27%16.57%5.24%

Becton, Dickinson and Company has higher revenue and earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$21.84B2.28$1.68B$3.3254.40
Baxter International$11.24B1.05-$957M-$2.07N/A

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Becton, Dickinson and Company pays an annual dividend of $4.20 per share and has a dividend yield of 2.3%. Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. Becton, Dickinson and Company pays out 126.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Baxter International pays out -1.9% of its earnings in the form of a dividend. Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company currently has a consensus price target of $187.67, suggesting a potential upside of 3.90%. Baxter International has a consensus price target of $22.45, suggesting a potential downside of 1.49%. Given Becton, Dickinson and Company's stronger consensus rating and higher possible upside, analysts clearly believe Becton, Dickinson and Company is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
1 Sell rating(s)
8 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.41
Baxter International
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Becton, Dickinson and Company beats Baxter International on 15 of the 19 factors compared between the two stocks.

How does Baxter International compare to Edwards Lifesciences?

Edwards Lifesciences (NYSE:EW) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Edwards Lifesciences currently has a consensus target price of $100.27, suggesting a potential upside of 13.66%. Baxter International has a consensus target price of $22.45, suggesting a potential downside of 1.49%. Given Edwards Lifesciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Edwards Lifesciences is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edwards Lifesciences
0 Sell rating(s)
6 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
2.74
Baxter International
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Edwards Lifesciences had 9 more articles in the media than Baxter International. MarketBeat recorded 11 mentions for Edwards Lifesciences and 2 mentions for Baxter International. Edwards Lifesciences' average media sentiment score of 0.97 beat Baxter International's score of 0.92 indicating that Edwards Lifesciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Edwards Lifesciences
8 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Edwards Lifesciences has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$6.07B8.37$1.07B$1.7450.70
Baxter International$11.24B1.05-$957M-$2.07N/A

Edwards Lifesciences has a net margin of 15.43% compared to Baxter International's net margin of -9.27%. Baxter International's return on equity of 16.57% beat Edwards Lifesciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Edwards Lifesciences15.43% 15.68% 12.05%
Baxter International -9.27%16.57%5.24%

79.5% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 90.2% of Baxter International shares are held by institutional investors. 0.3% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.2% of Baxter International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Edwards Lifesciences has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Summary

Edwards Lifesciences beats Baxter International on 13 of the 16 factors compared between the two stocks.

How does Baxter International compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Baxter International (NYSE:BAX) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, IDEXX Laboratories had 11 more articles in the media than Baxter International. MarketBeat recorded 13 mentions for IDEXX Laboratories and 2 mentions for Baxter International. Baxter International's average media sentiment score of 0.92 beat IDEXX Laboratories' score of 0.68 indicating that Baxter International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IDEXX Laboratories
4 Very Positive mention(s)
1 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Baxter International
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

IDEXX Laboratories has a net margin of 25.03% compared to Baxter International's net margin of -9.27%. IDEXX Laboratories' return on equity of 71.96% beat Baxter International's return on equity.

Company Net Margins Return on Equity Return on Assets
IDEXX Laboratories25.03% 71.96% 33.60%
Baxter International -9.27%16.57%5.24%

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

IDEXX Laboratories has higher earnings, but lower revenue than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEXX Laboratories$4.30B9.37$1.06B$14.2235.98
Baxter International$11.24B1.05-$957M-$2.07N/A

IDEXX Laboratories has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

IDEXX Laboratories presently has a consensus price target of $747.00, indicating a potential upside of 46.00%. Baxter International has a consensus price target of $22.45, indicating a potential downside of 1.49%. Given IDEXX Laboratories' stronger consensus rating and higher probable upside, equities analysts plainly believe IDEXX Laboratories is more favorable than Baxter International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60
Baxter International
2 Sell rating(s)
9 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

IDEXX Laboratories beats Baxter International on 13 of the 16 factors compared between the two stocks.

Get Baxter International News Delivered to You Automatically

Sign up to receive the latest news and ratings for BAX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BAX vs. The Competition

MetricBaxter InternationalHealthcare Equipment & Supplies IndustryHealthcare SectorNYSE Exchange
Market Cap$11.79B$5.55B$7.24B$23.10B
Dividend Yield0.18%1.80%2.57%3.62%
P/E Ratio-11.0125.34275.4928.21
Price / Sales1.0572.49646.0120.34
Price / Cash4.0132.6476.2536.36
Price / Book1.925.6910.464.67
Net Income-$957M$151.55M$3.49B$1.07B
7 Day Performance-4.25%0.66%0.59%-1.64%
1 Month Performance-13.56%-3.33%-1.74%-3.60%
1 Year Performance-1.02%6.79%18.13%8.41%

Baxter International Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BAX
Baxter International
1.3212 of 5 stars
$22.79
-1.0%
$22.45
-1.5%
-1.0%$11.79B$11.24BN/A37,500
AMN
AMN Healthcare Services
1.78 of 5 stars
$34.16
+2.5%
$36.00
+5.4%
+82.1%$1.29B$2.73B12.752,664
DVA
DaVita
4.6558 of 5 stars
$189.66
+4.5%
$233.43
+23.1%
+41.3%$11.58B$13.64B15.5278,000
BDX
Becton, Dickinson and Company
2.9838 of 5 stars
$183.21
+3.0%
$187.67
+2.4%
-3.6%$49.00B$21.84B55.1872,000
EW
Edwards Lifesciences
4.2722 of 5 stars
$85.58
+1.4%
$100.27
+17.2%
+18.6%$48.58B$6.07B49.1816,000

Related Companies and Tools


This page (NYSE:BAX) was last updated on 9/20/2026 by MarketBeat.com Staff.
From Our Partners